Life Sciences

The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK
12 April 2018

The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK

Humedics GmbH, a specialist in real-time measurement of individual liver function, today announced that the company has received Marketing Authorization for its diagnostic...

Read the press release
Adisseo and Seventure Partners announce €24m First Close of AVF, a New Fund Dedicated to Innovative Animal Health and  Nutrition
21 March 2018

Adisseo and Seventure Partners announce €24m First Close of AVF, a New Fund Dedicated to Innovative Animal Health and Nutrition

Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in Life science microbiome investment, today announces that it has launched AVF, the...

Read the press release
MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
8 March 2018

MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation

MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in...

Read the press release
Seventure Partners Life Sciences Investing Update – H2 2017
18 January 2018

Seventure Partners Life Sciences Investing Update – H2 2017

“2017 ended on a high note. Our Health For Life Capital™ investment vehicle has backed some truly remarkable disruptive technologies over the second half of the year and...

Read the press release
Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome
7 December 2017

Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome

VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...

Read the press release
Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy
1 December 2017

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy

New collaborations with Leiden University Medical Center and the Mitchell Cancer Institute focused on melanoma and cancers of the bladder, head and neck, and kidneys

Read more
Seventure Partners announces the trade sale of its portfolio company Cambrooke Therapeutics, Inc. to Ajinomoto Co. Inc
10 November 2017

Seventure Partners announces the trade sale of its portfolio company Cambrooke Therapeutics, Inc. to Ajinomoto Co. Inc

Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces the trade sale of...

Read the press release
Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers
30 October 2017

Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers

ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its...

Read the press release